Vascular-targeting agent

A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.^[1]

VTAs can be small-molecule or ligand-based.

Small-molecule VTAs include:

microtubule destabilizing drugs such as combretastatin A-4 disodium phosphate (CA4P), ZD6126, AVE8062, Oxi 4503
vadimezan (ASA404)

Clinical trials

Phase II : ZD6126, CA4P, plinabulin (NPI-2358)^[2]^[3]^[4]

Phase III : DMXAA (ASA404).

References

↑ "Vascular Targeting Agents as Cancer Therapeutics" (PDF). 2004. {{cite journal}}: Cite journal requires |journal= (help)
↑ "NPI-2358". clinicaltrials.gov.
↑ Monica M. Mita; et al. (2010). "Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas". Clin Cancer Res. 16 (23): 5892–5899. doi:10.1158/1078-0432.CCR-10-1096. PMID 21138873.
↑ Staff (2009). "Clinical Trials Update". Genetic Engineering & Biotechnology News. 29 (8): 58.

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "Vascular Targeting Agents as Cancer Therapeutics" (PDF). 2004. {{cite journal}}: Cite journal requires |journal= (help)

[2] "NPI-2358". clinicaltrials.gov.

[3] Monica M. Mita; et al. (2010). "Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas". Clin Cancer Res. 16 (23): 5892–5899. doi:10.1158/1078-0432.CCR-10-1096. PMID 21138873.

[Staff2009-4] Staff (2009). "Clinical Trials Update". Genetic Engineering & Biotechnology News. 29 (8): 58.

[1]

[2]

[3]

[4]